Lynn Bodarky Joins HiFiBiO Therapeutics as SVP, Global Head of Business Development and Alliance Management May 9, 2022 By sarahjibrin
May 9, 2022 By sarahjibrin Lynn Bodarky Joins HiFiBiO Therapeutics as SVP, Global Head of Business Development and Alliance Management
Apr 27, 2022 By sarahjibrin HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB200301 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 18, 2022 By sarahjibrin HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatment
Apr 18, 2022 By sarahjibrin Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors
Apr 18, 2022 By sarahjibrin Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization
Apr 4, 2022 By sarahjibrin HiFiBiO Therapeutics Announces Three Presentations at 2022 American Association for Cancer Research (AACR) Annual Meeting
Jan 10, 2022 By sarahjibrin HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB301001
Nov 1, 2021 By sarahjibrin HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200301
Sep 23, 2021 By sarahjibrin HiFiBiO Therapeutics Contributes to CoVIC-Led Science Publication on SARS-CoV-2 Spike Antibodies Effective Against Variants of Concern
